Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Filing

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 22, 2022 8:51am

105 Views

Post# 34842612

RE:RE:RE:RE:RE:Filing

The 1st and 2nd tranche deal with the convertible and look like the most attainable.

palinc2000 wrote:

I dont think parnership payments would be considered as revenue..
BTW the growth in revenue is nothing new.You hesrd it from me before !!! Lol

qwerty22 wrote:

The growth in revenue if it just came from the approved drugs would be impressive. Quite challenging with just Tesa and Trog?

Would partnership payments count as revenue? The issue with those is they are unpredictable in terms of when they land.

Do they have another revenue stream in mind?

The revenue numbers do make you think.

PWIB123 wrote: THTX wouldn't have agreed to this if they didn't believe the milestones were achievable. There might be some stretch objectives toward the end, but we can rest assured that the company thinks the funding amounts achievable are enough to get them where they need to go to bridge the next gap or gaps with enough capital to show new evidence that will release even more funding in the future.